Novo’s CagriSema delivers 12.4% weight loss in diabetes trial

Novo’s CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial versus 9.1% for low-dose tirzepatide. The weekly injection is targeted for launch early next year.